Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intranasal boosting induces variant-specific responses in SARS-CoV-2 vaccine-imprinted mice.

Nature communications·2026
Same authorSame journal

AAV vectors for cancer gene therapy.

Advances in cancer research·2026
Same author

Neural stem cell delivery of oncolytic CRAd-S-pk7 immunotherapy for stage 3 ovarian cancer: Dose-regimen studies.

Molecular therapy. Oncology·2026
Same author

Long-acting interleukin-7 improves the efficacy of oncolytic viral therapy in glioblastoma.

Nature communications·2026
Same author

An intranasal adenoviral-vectored vaccine protects against highly pathogenic avian influenza H5N1 in naive and antigen-experienced animals.

Cell reports. Medicine·2026
Same author

Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Frontiers in immunology·2025

Related Experiment Video

Updated: May 18, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Chapter two--Adenovirus strategies for tissue-specific targeting.

Matthew S Beatty1, David T Curiel

  • 1Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine in St Louis, St Louis, Missouri, USA.

Advances in Cancer Research
|October 2, 2012
PubMed
Summary

Adenovirus gene therapy for cancer shows promise but requires retargeting vectors to cancer cells lacking native receptors. Strategies include adapter-based and genetic modifications for improved tumor targeting and clinical application.

More Related Videos

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
14:55

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

Related Experiment Videos

Last Updated: May 18, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
14:55

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Adenovirus vectors are promising for cancer gene therapy due to their therapeutic delivery capabilities.
  • A significant challenge is the limited expression of native adenovirus receptors on many cancer cell types, hindering effective targeting.
  • Overcoming this requires strategies to retarget adenovirus to non-native cellular surface receptors.

Purpose of the Study:

  • To review biological hurdles and strategies for retargeting adenovirus vectors for cancer gene therapy.
  • To cover advancements in both adapter-based and genetic manipulation-based targeting approaches.
  • To discuss the clinical translation of these adenovirus targeting strategies.

Main Methods:

  • Review of existing literature on adenovirus biology and targeting strategies.
  • Analysis of adapter-based methods for redirecting adenovirus to alternative receptors.
  • Examination of genetic engineering techniques to modify adenovirus for enhanced cancer cell recognition.

Main Results:

  • Several strategies have been developed to overcome the lack of native adenovirus receptors on cancer cells.
  • Adapter-based and genetic manipulation methods show progress in retargeting adenovirus vectors.
  • These targeting strategies are increasingly being translated into clinical settings.

Conclusions:

  • Retargeting adenovirus vectors is crucial for effective cancer gene therapy when native receptors are absent.
  • Both adapter-based and genetic approaches offer viable solutions for enhancing adenovirus tumor targeting.
  • The clinical application of these advanced adenovirus targeting strategies is advancing.